ABBV-295
A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity
AbbVie · Phase 1 · Active, not recruiting · Enrollment 80
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| ABBV-295 or Placebo-Group 1 | n/r | n/r | n/r | n/r | n/r |
| ABBV-295 or Placebo-Group 2 | n/r | n/r | n/r | n/r | n/r |
| ABBV-295 or Placebo-Group 3 | n/r | n/r | n/r | n/r | n/r |
| ABBV-295 or Placebo-Group 3 Extension | n/r | n/r | n/r | n/r | n/r |
| ABBV-295 or Placebo-Group 4 | n/r | n/r | n/r | n/r | n/r |
| ABBV-295 or Placebo-Group 4 Extension | n/r | n/r | n/r | n/r | n/r |
| ABBV-295 or Placebo-Group 5 | n/r | n/r | n/r | n/r | n/r |
| ABBV-295 or Placebo-Group 6 | n/r | n/r | n/r | n/r | n/r |
A count stays a count. This page does not turn a count into a percent.